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Background: Cardiovascular manifestations in COPD include increased arterial stiffness,
ischaemic heart disease, chronic heart failure and cor pulmonale. We hypothesised that
sub-clinical right (RV) and left ventricular (LV) dysfunction occurs in patients with COPD,
related to the severity of airflow obstruction, arterial stiffness and systemic inflammation.
Methods: Thirty six patients and 14 controls, all free of overt cardiovascular disease under-
went tissue Doppler echocardiography, spirometry, measurement of aortic pulse wave velocity
(PWV) and venous sampling for inflammatory markers.
Results: Mean LV myocardial strain and strain rate were less in patients than controls,
p< 0.05. LV isovolumic relaxation time (IVRT) was prolonged in patients (125  15.2 ms)
compared with controls (98.2 21.1 ms), p< 0.01, indicating LV diastolic dysfunction. The
RV free wall strain and strain rate were less in patients than controls, both p< 0.05, indicating
RV systolic dysfunction. Patients had sub-clinical pulmonary arterial hypertension with
a greater RV myocardial relaxation time and Tei index, both p< 0.01. Patients with mild
airways obstruction had LV and RV dysfunction and evidence of increased RV afterload
compared with controls. In multivariate analyses aortic PWV predicted LV IVRT, p< 0.01, while
FEV1 predicted RV Tei index and myocardial relaxation time, both p< 0.01.)2920 716948; fax: þ44(0)2920 716416.
.uk (D.J. Shale).
0 Elsevier Ltd. All rights reserved.
1172 R. Sabit et al.Conclusions: Patients with COPD have sub-clinical left ventricular dysfunction related to arte-
rial stiffness, and right ventricular dysfunction related to airways obstruction. Both right and
left ventricular dysfunction are present in patients with mild airways obstruction suggesting
that cardiac co-morbidities commence early in the development of COPD.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is associated
with considerable morbidity and is predicted to become the
third leading cause of death worldwide by 2020.1,2 Early in
the course of the disease respiratory symptoms predomi-
nate, while later systemic complications include osteopo-
rosis,3 loss of fat free mass (FFM)3 and cardiovascular
disease.4,5 Cardiovascular complications in patients with
COPD include cor pulmonale,6 a 2e3 fold excess cardio-
vascular event risk even after allowing for confounders such
as smoking,7 and a greater than four fold excess risk of
chronic heart failure (CHF).8
Arterial stiffness, an independent predictor of cardio-
vascular outcome9,10 was increased in patients with COPD,
free of cardiovascular disease, suggesting acceleration of
age dependent stiffening.11 It was present even in mild
severity airways obstruction, which suggests stiffening
develops in early lung disease in parallel with asymptomatic
changes in pulmonary arterial pressure and right ventricular
function.12,13 Long-term effects of increased arterial stiff-
ness in COPD are unknown, but might include cardiac
adaptations similar to those in normal aging,14e17 systemic
hypertension18 and diastolic heart failure.19 Such changes
in cardiac structure and function may underlie the
increased risk of cardiovascular disease in COPD.
Echocardiographic evaluation of left and right ventric-
ular function in patients with COPD is challenging, mainly
due to lung hyperinflation but may be improved using tissue
Doppler echocardiography (TDE) to study regional systolic
and diastolic function, myocardial and annular velocities
and myocardial deformation indices such as strain and
strain rate. TDE allows precise and quantitative measure-
ment of myocardial function and can therefore detect sub-
clinical changes.20
A low FFM is associated with increased morbidity and
mortality in patients with COPD,21,22 and is partly a result of
altered protein metabolism, where protein turnover
predominates over protein synthesis.23 Since cardiac muscle
is also a protein rich tissue, it may be affected by similar
proteolytic processes which may result in loss of cardiac
muscle mass and impairment of myocardial function.
We hypothesised that patients with COPD, clinically free
of cardiovascular disease, would have sub-clinical left
ventricular (LV) and right ventricular (RV) dysfunction
related to the severity of airways obstruction, arterial
stiffness, systemic inflammation and changes in body
composition. To test this we determined ventricular func-
tion by echocardiography with tissue Doppler imaging, and
related structural and functional changes to these variables
in clinically stable patients with a wide range of severity of
COPD.Methods
Subjects
Thirty six consecutive patientswith confirmedCOPD24 and 14
current or ex-smokers were recruited from primary and
secondary care and studied. All had participated in a study of
arterial stiffness.11 Subjects were excluded from the study if
they were receiving long-term oxygen therapy or mainte-
nance oral corticosteroids, or had known heart disease,
malignancy, cor pulmonale or any other inflammatory or
metabolic condition. Twenty patients had a negative Weber
protocol treadmill exercise test. A further three had a recent
normal coronary angiogram and Bruce protocol exercise
test. Nine refusing an exercise test had a normal resting ECG.
Of those completing an exercise test the mean duration was
7.5 min, seven achieving theirmaximal predicted heart rate.
Exercise was stopped by breathlessness with no chest
discomfort or ECG evidence of ischaemia: horizontal or
down-sloping ST segment depression 1 mm. The study had
Local Research Ethics Committee approval and all subjects
gave written, informed consent.
Body composition, lung function and
questionnaires
Height and weight were determined barefoot in light
clothing and body mass index (BMI, kg/m2) derived. Whole
body fat free mass (FFM) was determined by Dual energy X-
ray Absorptiometry (Hologic Discovery, Bedford, MA) and
expressed as a height squared ratio to give whole body FFM
index (FFMI). Similarly, the sum of lower limb FFM was
expressed as a height2 related index. A low whole body
FFMI was defined as less than the lower 5th percentile of
a cohort of gender-matched control subjects.3 Forced
expiratory volume in one second (FEV1) and forced vital
capacity (FVC) were determined by spirometry and the
FEV1/FVC ratio and FEV1 and FVC % predicted values
calculated.24 Pulmonary diffusion capacity was determined
by the single breath-hold carbon monoxide transfer factor
corrected for alveolar volume (KCO) in the patients (Pul-
molab 501 system, Morgan Medical, Kent, UK). Arterialized
ear lobe blood gases were determined at rest. All subjects
completed an Epworth sleepiness score questionnaire to
exclude obstructive sleep apnoea syndrome. The median
score was 4, range 0e9.
Cardiovascular testing
Subjects were studied after an overnight fast and 6 h
abstinence from caffeine, tobacco, inhaled short-acting b2
agonist and antihypertensive medication.





Age (years) 66.5 8.9 67.0 8.8
Gender 19M, 17F 9M, 5F
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Echocardiography was performed blind by one operator
(JE), using a Vivid 7 ultrasound system (GE, Horten,
Norway). Annular velocities were measured in real time
using pulsed wave tissue Doppler, while myocardial wall
velocities and derived strain and strain rate curves were
measured offline using dedicated software (EchoPAC, GE,
Horten, Norway). Regional myocardial function was
measured at the basal portion of the RV free wall, and at
the basal portion of all 6 LV walls and averaged. All vari-
ables were the average of measurements in three consec-
utive cardiac cycles. Dimensions of the LV and RV were
determined from M-mode recordings in the parasternal
long-axis view. LV mass was calculated using the cubed
formula. Ejection fraction and mean pulmonary arterial
pressure were estimated using Simpson’s biplane method
and measurement of tricuspid regurgitant velocity respec-
tively (Table 1).25e28 Further details of individual echocar-
diographic parameters, their measurement and derivation
of variables are given in the online methods supplement.
A summary of all echo parameters and their relationship to
cardiac function is presented in Table 1.
Intra-observer variability of TDE measurements was
assessed by re-analysing a number of offline parameters in
10 randomly selected subjects. Intra-observer variability
was calculated using BlandeAltman analysis and was <12%
for all measurements.
Arterial stiffness
Peripheral blood pressure, pulse wave analysis and carotid-
femoral (aortic) pulse wave velocity (PWV) were deter-
mined.11,29 Further details of these measurements are
available in the online methods supplement.
Inflammatory mediators and protein breakdown
Venous blood was collected for fasting glucose, lipids,
interleukin (IL)-6 and tumour necrosis factor (TNF)-




























timeurine sample was collected for measurement of pseudour-
idine (PSU) and creatinine by high performance liquid
chromatography. The PSU concentration was expressed as
a ratio to creatinine to correct for dilution.
Statistical analysis
A formal sample size calculation was performed prior to the
commencement of the study and was based on the results
of a similar study in patients with cystic fibrosis.30 Data
were analysed with the Statistical Package for the Social
Sciences (SPSS, Chicago, IL), version 12.0. Positively
skewed data were Log10 transformed. Analyses included the
c2 test, independent t test, Pearson’s correlations, one way
analysis of variance with Post hoc Tukey analysis and




Patients and controls were similar for age, gender, height,
BMI, FFMI, lipid profile and fasting glucose (Table 2).
Hypertension was present in 33% of patients and 14% of
controls, pZ 0.25. Statin use was similar between groups
and no subjects were taking beta blockers. All patients
received an inhaled short-acting b2 agonist bronchodilator;
15 (42%) a long-acting b2 agonist; 19 (53%) an anti-
cholinergic bronchodilator; and 15 (42%) an inhaledHeight (cm) 166 7 169 6
BMI (kg/m2) 27.3 4.9 26.9 3.2
Whole body FFMI (kg/m2) 17.2 2.2 18.1 2.1
Lower limb FFMI (kg/m2) 5.2 0.8* 5.8 0.9
PSU (mmol/mmol creatinine) 34.7 1.3 28.8 1.2
LDL cholesterol (mmol/L) 3.64 0.92 3.26 0.71
Fasting glucose (mmol/L) 5.31 0.5 5.56 0.51
Smoking pack-year history 49.9 15.6z 16.4 11.1
Serum IL-6 (pg/ml)a 2.14 1.6y 1.29 1.5
TNF-a sr1 (pg/ml)a 1380 1.4 1259 1.3
TNF-a sr2 (pg/ml)a 2399 1.4 2188 1.3
% Predicted FEV1 56.9 20.6z 103.6 15.2
% Predicted FVC 81.7 23.5z 104.6 12.1
FEV1/FVC % 53.8 10.9z 78.2 4.6
Data are presented as mean standard deviation unless stated
otherwise.
*p< 0.05, yp< 0.01, zp< 0.001 in comparison with control
subjects.
Definition of abbreviations: BMI, body mass index; FFMI, fat
free mass index; LDL, low density lipoprotein; IL-6, interleukin
6; TNF-a sr, tumour necrosis factor a soluble receptor; FEV1,
forced expiratory volume in 1 s; FVC, forced vital capacity.
a Geometric mean.
1174 R. Sabit et al.corticosteroid. More patients, 16, were current smokers
than controls, 2 (p< 0.01), and pack-year exposure was
greater than controls (p< 0.01). The median (range) arte-
rial PaO2 for the patients was 70 (57e88) mmHg.
Left ventricular structure and function
Mean LV mass, posterior wall thickness and ejection
fraction were similar in patients and controls (Table 3).
Compared with controls, patients had impaired longitudinal
and regional systolic function with a reduced mean mitral
annular peak systolic velocity (p< 0.05), average LV strain
(p< 0.01) and peak systolic strain rate (p< 0.001) (Fig. 1a
and b) (Table 3). Patients had diastolic dysfunction with
a longer IVRT and a greater E/EA (both p< 0.01).
Aortic stiffness and left ventricular function
While peripheral and central blood pressure was similar
between patients and controls, aortic PWV was 22% greater
in patients, p< 0.001. Heart rate (p< 0.001) and augmen-
tation index (AIx) (p< 0.05) were also greater in patients
(Table 3). In patients, aortic PWV was related to LV diastolic
function; E/EA (rZ 0.55, p< 0.01); mitral E/A (rZ0.38,
p< 0.05); mitral annular e/a (rZ0.45, p< 0.01); and
IVRT (rZ0.46, p< 0.01), but not to any measures of
systolic function. AIx was unrelated to systolic or diastolic





Resting heart rate (bpm) 75.4 8.8z 66.9 10.6
LV mass* (g) 186.2 1.41 190.0 1.26
LV mass/BSA (g/m2) 104.5 27.7 103.8 24.5
LV mass/FFMI 4.1 0.9 3.8 0.8
Mitral E/A 0.8 0.2 0.9 0.1
IVRT (ms) 125.0 15.2y 98.2 21.1
Mitral annular
relaxation (e/a)
0.8 0.4 0.9 0.3
E/EA 10.7 2.6y 7.9 1.6
Fractional shortening (%) 37 5* 42 6
Ejection fraction (%) 63 4 67 6
LV peak systolic
velocity (cm/s)
5.5 0.9 5.8 0.6
LV systolic strain (%) 18.2 2.8y 21.0 2.5
LV systolic strain rate (s1) 1.3 0.2z 1.7 0.2
Lateral mitral annular peak
systolic velocity (cm/s)




AIx (%) 32.5 8.6* 26.0 5.4
Aortic PWV (m/s) 11.5 2.9z 9.45 1.3
Data are presented as mean standard deviation.
*p< 0.05, yp< 0.01, zp< 0.001 in comparison with control
subjects.
Definition of abbreviations: bpm, beats per minute; BSA, body
surface area; AIx, augmentation index; PWV, pulse wave
velocity; IVRT, isovolumetric relaxation time; LV, left
ventricular.Right ventricular structure and function
The RV free wall thickness was 31% greater in patients than
controls, p< 0.01 (Table 4). Impaired longitudinal and
global systolic function occurred in patients, who had
a lower mean tricuspid annular peak systolic velocity
(p< 0.001) and a greater Tei index (p< 0.001). Patients
also had regional systolic dysfunction with lower basal peak
systolic velocity (p< 0.01), strain (p< 0.001), peak systolic
strain rate (p< 0.001) (Fig. 1a and b), and isovolumic
acceleration (p< 0.01).
Indicators of raised pulmonary arterial pressure
Estimated mean pulmonary arterial pressure was similar
between subject groups, but could not be determined in all
subjects by the regurgitant tricuspid jet. Only one patient
had a peak systolic pressure of >35 mmHg. However,
pulmonary arterial hypertension was indicated by a greater
Tei index, a longer basal free wall myocardial relaxation
time (p< 0.001) and a shorter pulmonary acceleration time
(p< 0.01) in the patients.
Severity of COPD and cardiovascular function
Patient subgroups were compared based on the severity of
airways obstruction: FEV1> 50% predicted (GOLD I and II,
nZ 20) and FEV1< 50% predicted (GOLD III and IV, nZ 16).
Both subgroups were similar for age and gender. LV systolic
dysfunction was present even in those with FEV1> 50%
predicted, with a lower strain (pZ 0.01), peak systolic
strain rate (p< 0.001) and a lower mean mitral annular
peak systolic velocity than controls (both p< 0.05). Both
patient subgroups had LV diastolic dysfunction with a pro-
longed IVRT compared with controls (both p< 0.01).
Right ventricular dysfunction was also present in
patients with milder lung disease, with a lower mean free
wall peak systolic velocity (p< 0.05), strain (p< 0.05) and
strain rate (p< 0.01) (Fig. 1a and b), and a lower mean
tricuspid annular peak systolic velocity (pZ 0.001) than in
controls. The Tei index was different between all groups.
The FEV1 was related to indices of pulmonary hyper-
tension: pulmonary acceleration time (rZ 0.35, p< 0.05);
RV free wall thickness (rZ0.37, p< 0.05) and myocardial
relaxation time (rZ0.41, p< 0.05) and Tei index
(rZ0.50, p< 0.01). KCO was related to RV free wall
thickness (rZ0.40, p< 0.05) and IVRT (rZ0.40,
p< 0.05). Arterial oxygen tension was also related to RV
free wall thickness (rZ0.33, p< 0.05), and myocardial
relaxation time (rZ0.35, p< 0.05).
Body composition and protein breakdown
Whole body FFM and FFMI were similar between groups, but
lower limb FFMI was less in patients than controls, p< 0.05,
and PSU excretion was greater in patients than controls,
p< 0.05 (Table 2). Patients were sub-grouped as normal or
low whole body FFMI, the latter for males <17.2 kg/m2 and
<13.7 kg/m2 for females. Nine patients and one control
subject had a low FFMI. The patient subgroups were similar
for age, gender and FEV1. LV mass (p< 0.01), peak systolic
Table 4 Right ventricular function and pulmonary arterial pressure.
Patients (nZ 36) Controls (nZ 14)
RV free wall thickness in diastole (cm) 0.59 0.14y 0.45 0.06
RV internal dimension in diastole (cm) 2.5 0.5 2.5 0.5
Estimated pulmonary arterial systolic pressure (mmHg) 22.9 2.1 (nZ 15) 20.3 3.2 (nZ 6)
Pulmonary acceleration time (ms) 188.7 27.0y 216.9 27.9
Tei index 0.10 0.05z 0.07 0.03
Lateral tricuspid annulus peak velocity (cm/s) 12.0 1.9z 14.2 1.6
Basal RV free wall
Peak systolic velocity (cm/s) 9.2 1.9* 10.8 1.8
Myocardial relaxation time (ms) 47.9 33.7z 12.6 16.6
Strain (%) 18.6 5.4z 24.3 2.6
Peak systolic strain rate (s1) 1.4 0.4z 1.8 0.4
Isovolumic acceleration (cm/s2) 1.6 0.6y 2.3 0.6
Data are presented as mean standard deviation.
*p< 0.05, yp< 0.01, zp< 0.001 in comparison with control subjects.
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longer (p< 0.05) in the patients with a low whole body FFMI
(Table 5). A low FFMI was associated with a longer mean RV
myocardial relaxation time (p< 0.01) and a greater Tei
index (both p< 0.05) (Table 5). Low FFMI patients had
lower mean PaO2 levels (p< 0.05) compared with normal
FFMI patients.
Inflammatory mediators
Circulating IL-6 was greater in patients, while TNF-a sr1 and
sr2 levels were similar (Table 2). In patients, Log10 IL-6 was
related to pulmonary acceleration time (rZ0.33,
p< 0.05); average LV strain (rZ0.32, p< 0.05) and
mitral annular e/a (rZ0.35, p< 0.05). There were no
relationships between the circulating IL-6, TNF-a sr 1 or 2
and total FFMI, PSU and LV mass.
Multivariate analysis
Predictors of LV systolic and diastolic function in the
patients were determined by multivariate analysis with LV
strain and IVRT respectively as dependent variables and
age, FEV1 % predicted, Log10 IL-6, peripheral mean arterialFigure 1 Left and right ventricular strain (a) and strain rate
represent 1 standard deviation. Open column represents controls;pressure (MAP), pack years smoked, whole body FFMI and
aortic PWV as independent variables. Whole body FFMI was
the only predictor of LV strain (r2Z 0.22, p< 0.01), while
aortic PWV was the only predictor of IVRT (r2Z 0.22,
p< 0.01). For predictors of global RV function and surro-
gate indices of pulmonary arterial pressure the same
independent variables were used in addition to PaO2, and %
predicted FEV1 was the only predictor of both RV Tei index
(r2Z 0.23, p< 0.01) and basal free wall myocardial relax-
ation time (r2Z 0.14, p< 0.05).
A similar analysis for LV mass as the dependent variable,
with age, gender, MAP, FEV1 % predicted, Log10 IL-6,
Log10 PSU, PaO2 and total body FFMI as independent vari-
ables, revealed that whole body FFMI (adjusted r2Z 0.56,
p< 0.01) and PSU (adjusted r2Z 0.06, p< 0.05) were the
only predictors. Substituting whole body FFMI with lower
limb FFMI in the same analysis revealed only the lower limb
FFMI (adjusted r2Z 0.48, p< 0.01) was a predictive
variable.
Subjects without hypertension
A subgroup analysis excluding subjects with hypertension
compared myocardial function in patients (nZ 24) and(b) in patients and controls. *p< 0.01,**p< 0.001. Error bars
grey column represents patients; , controls; patients.
Table 5 Comparisons between patients with a low or







38.1 1.27 33.6 1.31
LV mass (g) 159.0 50.0* 209.6 65.8
LV peak systolic velocity (cm/s) 5.25 0.84y 6.13 0.79
LV strain (%) 15.9 1.1y 18.3 2.0
IVRT (ms) 135.2 16.0* 123.5 12.5
RV myocardial relaxation
time (ms)
75.1 35.9y 38.8 28.1
Tei index 0.17 0.06* 0.13 0.05
PaO2 (mmHg) 65.4 6.7* 71.5 6.9
Data are presented as mean standard deviation.
*p< 0.05, yp< 0.01 in comparison with normal FFMI subjects.
1176 R. Sabit et al.control subjects (nZ 12). Similar to whole group analysis,
patients with COPD had evidence of regional systolic LV
dysfunction, LV diastolic dysfunction, RV systolic dysfunc-
tion and evidence of raised pulmonary arterial pressure.
Discussion
Sub-clinical left ventricular (LV) and right ventricular (RV)
systolic and diastolic dysfunction was present in patients
with COPD, free of overt cardiovascular disease, when
compared with age and gender-matched smoking controls.
The presence of LV and RV dysfunction in patients with
mild severity airflow limitation suggests that cardiac
complications may start to develop from early in the
progress of lung disease and may remain sub-clinical for
a long period. Both LV and RV dysfunction were associated
with increases in their afterload due to increased aortic
stiffness and raised pulmonary arterial pressure
respectively.
Although LV ejection fraction was not different between
patients and controls, other validated measures such as LV
strain, strain rate and mitral annular peak systolic velocity
were reduced in our patients indicating potential loss of
regional LV contractility and impaired longitudinal LV
systolic function. A number of animal and human studies
have demonstrated that strain and strain rate reflect
regional left ventricular function, while mitral annular peak
systolic velocity has been shown to correlate with radio-
nuclide ejection fraction.25,31,32 LV systolic dysfunction in
our patients was related to the severity of airways
obstruction, FFMI and IL-6, though only FFMI was predic-
tive. This suggests impairment is linked to the
inflammatory-catabolic state in COPD, an interpretation
supported by the LV mass also being predicted by whole
body FFMI and lower limb FFMI, and to a lesser degree by
PSU excretion, an indicator of protein breakdown in COPD.3
This catabolic state is analogous to that reported in CHF,24
and in our patients the catabolic drive appeared to offset
any stimulus to LV hypertrophy in response to increased
arterial stiffness.
Our findings of diastolic dysfunction in patients with
COPD, indicated by an increased IVRT and E/EA, aresupported by two recent studies.33,34 LV diastolic dysfunc-
tion in patients with COPD may be due to abnormalities in
LV pre-load and/or afterload. Chest wall hyperinflation
secondary to emphysema, may affect LV diastolic function
by impairing LV filling and pre-load. This interpretation is
supported by the inverse relationship between KCO and
IVRT. However, IVRTwas only predicted by aortic PWV in an
analysis including other accepted risk factors, which
suggests a possible causal mechanism.15,35,36 The earlier
return of the reflected arterial wave augments aortic
systolic pressure increasing LV afterload, while the
concomitant reduction of aortic diastolic blood pressure
may reduce coronary perfusion leading to sub-endocardial
ischaemia. Both of these effects lead to myocardial
fibrosis with impaired myocardial relaxation.29 Thus, our
patients are likely to have ventricularearterial stiffening
with impaired systolic and diastolic function in the absence
of overt cardiovascular disease.37 In this context our find-
ings suggest a possible potential mechanism underlying the
excess risk of coronary heart disease and CHF in COPD and
possibly the relationship between airways obstruction,
arterial stiffness and cardiovascular disease in the general
population.7,10,38e41
Impaired RV systolic function, and in particular, reduced
contractility as indicated by a lower free wall strain, strain
rate and isovolumetric acceleration was present in the
patients including those with even mild disease, when
compared with controls.12,13,27,42,43 None of our patients
had clinical evidence of cor pulmonale and estimation of
pulmonary arterial pressure using the tricuspid regurgitant
jet did not separate patient and control groups; being
quantifiable in less than half our subjects with only one
with a pressure >35 mmHg. However, changes in surrogate
indices of pulmonary arterial hypertension, including RV
free wall myocardial relaxation time,44 pulmonary accel-
eration time,45 and Tei index,46 indicated RV functional
changes consistent with a degree of increased pulmonary
vascular resistance and increased afterload in patients with
both mild and severe lung disease. This confirms the find-
ings of RV dysfunction without clinical evidence of cor
pulmonale in patients with COPD where such features were
mainly associated with pressures >35 mmHg, though,
similar to our study, systolic strain and strain rate reduc-
tions were present in patients with pressures <35 mmHg.12
The relationship of RV dysfunction and surrogate markers of
pulmonary artery pressure to FEV1, PaO2 and KCO was
expected and confirms previously reported relationships.12
The presence of sub-clinical RV dysfunction and indirect
evidence of increased pulmonary arterial resistance in both
mild and severe airways obstruction supports the early
occurrence of pulmonary vascular changes and RV impair-
ment without evidence of overt pulmonary hypertension in
COPD. Sub-clinical RV dysfunction was reported to be
related to the severity of lung disease and chronic inflam-
mation in adults with cystic fibrosis free of cor pulmonale
and in diabetes mellitus and rheumatoid arthritis.30,47,48
While diagnosing cor pulmonale has negative prognostic
implications,6 the significance of sub-clinical RV dysfunc-
tion is currently unknown. Use of TDE to quantify RV
function and pulmonary artery pressure may have potential
in longitudinal studies of the natural history of cor pulmo-
nale and possibly in therapeutic trials.
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The differences in tobacco exposure between patient and
control groups are a potential confounder, hence pack-year
exposure was included in our regression analysis. Subjects
were asked to refrain from smoking 6 h before testing since
the acute effects of smoking include an increase in aortic
PWV and impairment of LV diastolic function.49,50 Inclusion
of subjects with hypertension is also open to criticism, so
MAP was included in regression analysis and there was no
difference in mean blood pressure indices between groups.
In addition, a subgroup analysis excluding subjects with
hypertension revealed similar results. We accept that the
cross sectional nature and relatively low subject numbers in
our study do not allow direct relationships between COPD
and cardiac function to be inferred. However, our study has
demonstrated strong associations which should be explored
further.
Conclusions
This study in clinically stable patients with a wide range of
severity of airways disease provides new evidence of sub-
clinical LV and RV dysfunction and suggests cardiovascular
co-morbidities may begin early in COPD and are often
occult. Left ventricular diastolic dysfunction was related to
arterial stiffness, indicating ventricularearterial stiffening,
while RV dysfunction was related to the severity of airways
obstruction.Acknowledgements
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